http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 31 Jul 2026 08:30:04 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Dividends/Organon+%28OGN%29+Declares+%240.02+Quarterly+Dividend%3B+0.6%25+Yield/26847229.html <p>Organon (NYSE: OGN) declared a quarterly dividend of $0.02 per share, or $0.08 annualized.</p> <p>The dividend will be payable on September 10, 2026, to stockholders of record on August 14, 2026, with an ex-dividend date of August 13, 2026.</p> <p>The annual yield on the dividend is 0.6 percent.</p> <p>For a dividend history and other dividend-related data on Organon (OGN) <a href="http://www.streetinsider.com/dividend_history.php?q=OGN">click here</a>.</p> http://www.streetinsider.com/Dividends/Organon+%28OGN%29+Declares+%240.02+Quarterly+Dividend%3B+0.6%25+Yield/26847229.html Fri, 31 Jul 2026 08:30:04 -0400 OGN http://www.streetinsider.com/Press+Releases/Organon+Announces+Quarterly+Dividend/26847228.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. </p><p> <b>About Organon</b> </p><p> Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of http://www.streetinsider.com/Press+Releases/Organon+Announces+Quarterly+Dividend/26847228.html Fri, 31 Jul 2026 08:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Announces+Quarterly+Dividend/26847228.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. </p><p> <b>About Organon</b> </p><p> Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of http://www.streetinsider.com/Press+Releases/Organon+Announces+Quarterly+Dividend/26847228.html Fri, 31 Jul 2026 08:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Announces+Quarterly+Dividend/26847228.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. </p><p> <b>About Organon</b> </p><p> Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of http://www.streetinsider.com/Business+Wire/Organon+Announces+Quarterly+Dividend/26847228.html Fri, 31 Jul 2026 08:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Announces+Quarterly+Dividend/26847228.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. </p><p> <b>About Organon</b> </p><p> Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of http://www.streetinsider.com/Business+Wire/Organon+Announces+Quarterly+Dividend/26847228.html Fri, 31 Jul 2026 08:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html <p>Organon (NYSE: OGN) presented results from a post hoc analysis of pooled Phase 3 data for its tapinarof cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota, according to a company press release.</p> <p>The analysis drew from the ADORING 1 and ADORING 2 pivotal trials, which enrolled 813 adults and children aged 2 years and older with moderate to severe atopic dermatitis. Participants were randomized 2:1 to tapinarof cream or vehicle once daily for eight weeks. The data were stratified into four age groups: 2–6 years, 7–11 years, 12–17 years, and 18 years and older. Most http://www.streetinsider.com/FDA/Organon+presents+tapinarof+cream+data+across+age+groups+at+SPD+meeting/26810869.html Fri, 24 Jul 2026 08:00:24 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html <ul class="bwlistdisc"> <li> The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD<b>®</b>) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 </li> <li> VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 </li> <li> Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of http://www.streetinsider.com/Press+Releases/New+Analysis+of+Phase+3+Pooled+Data+for+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Demonstrates+Early%2C+Consistent+Improvements+in+Atopic+Dermatitis+Patients+Across+Pediatric+Age+Groups+and+in+Adults%C2%B9/26810848.html Fri, 24 Jul 2026 08:00:00 -0400 A.06822034 A.36747586 A.60012013 A.60012014 O.00036564 O.20026344 O.38236026 O.50635033 O.54741979 OGN